Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells

Rosamund Chapman, Enid Shephard, Helen Stutz, Nicola Douglass, Vasan Sambandamurthy, Irene Garcia, Bernhard Ryffel, William Jacobs, Anna Lise Williamson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain (BCGΔpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable vaccines BCG[pHS400] (BCG-Gag) and BCGΔpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG, and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8 + T cells were detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4 + T cells when priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a surrogate vaccinia virus challenge.

Original languageEnglish (US)
Article numbere32769
JournalPloS one
Volume7
Issue number3
DOIs
StatePublished - Mar 29 2012

Fingerprint

auxotrophs
T-cells
Mycobacterium bovis
Human immunodeficiency virus 1
BCG Vaccine
HIV-1
AIDS Vaccines
T-lymphocytes
BCG vaccine
T-Lymphocytes
Viruses
Vaccinia virus
mice
Genes
gag Gene Products
Immune system
promoter regions
vaccines
Protein Sorting Signals
Mycobacterium bovis BCG

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chapman, R., Shephard, E., Stutz, H., Douglass, N., Sambandamurthy, V., Garcia, I., ... Williamson, A. L. (2012). Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells. PloS one, 7(3), [e32769]. https://doi.org/10.1371/journal.pone.0032769

Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells. / Chapman, Rosamund; Shephard, Enid; Stutz, Helen; Douglass, Nicola; Sambandamurthy, Vasan; Garcia, Irene; Ryffel, Bernhard; Jacobs, William; Williamson, Anna Lise.

In: PloS one, Vol. 7, No. 3, e32769, 29.03.2012.

Research output: Contribution to journalArticle

Chapman, R, Shephard, E, Stutz, H, Douglass, N, Sambandamurthy, V, Garcia, I, Ryffel, B, Jacobs, W & Williamson, AL 2012, 'Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells', PloS one, vol. 7, no. 3, e32769. https://doi.org/10.1371/journal.pone.0032769
Chapman, Rosamund ; Shephard, Enid ; Stutz, Helen ; Douglass, Nicola ; Sambandamurthy, Vasan ; Garcia, Irene ; Ryffel, Bernhard ; Jacobs, William ; Williamson, Anna Lise. / Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells. In: PloS one. 2012 ; Vol. 7, No. 3.
@article{d008196fa7a2496eb3a593ac47f371af,
title = "Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells",
abstract = "A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain (BCGΔpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable vaccines BCG[pHS400] (BCG-Gag) and BCGΔpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG, and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8 + T cells were detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4 + T cells when priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a surrogate vaccinia virus challenge.",
author = "Rosamund Chapman and Enid Shephard and Helen Stutz and Nicola Douglass and Vasan Sambandamurthy and Irene Garcia and Bernhard Ryffel and William Jacobs and Williamson, {Anna Lise}",
year = "2012",
month = "3",
day = "29",
doi = "10.1371/journal.pone.0032769",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells

AU - Chapman, Rosamund

AU - Shephard, Enid

AU - Stutz, Helen

AU - Douglass, Nicola

AU - Sambandamurthy, Vasan

AU - Garcia, Irene

AU - Ryffel, Bernhard

AU - Jacobs, William

AU - Williamson, Anna Lise

PY - 2012/3/29

Y1 - 2012/3/29

N2 - A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain (BCGΔpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable vaccines BCG[pHS400] (BCG-Gag) and BCGΔpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG, and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8 + T cells were detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4 + T cells when priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a surrogate vaccinia virus challenge.

AB - A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain (BCGΔpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable vaccines BCG[pHS400] (BCG-Gag) and BCGΔpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG, and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8 + T cells were detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4 + T cells when priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a surrogate vaccinia virus challenge.

UR - http://www.scopus.com/inward/record.url?scp=84859069751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859069751&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0032769

DO - 10.1371/journal.pone.0032769

M3 - Article

C2 - 22479338

AN - SCOPUS:84859069751

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e32769

ER -